Next Article in Journal / Special Issue
Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2
Previous Article in Journal
Physical and Chemical Barriers in the Larval Midgut Confer Developmental Resistance to Virus Infection in Drosophila
Previous Article in Special Issue
Genomic Surveillance of Circulating SARS-CoV-2 in South East Italy: A One-Year Retrospective Genetic Study
Article

Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

1
Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA
2
A.T Kearney, Inc., Chicago, IL 60606, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Luis Martinez-Sobrido and Fernando Almazan Toral
Viruses 2021, 13(5), 893; https://doi.org/10.3390/v13050893
Received: 13 March 2021 / Revised: 5 May 2021 / Accepted: 6 May 2021 / Published: 12 May 2021
(This article belongs to the Collection SARS-CoV-2 and COVID-19)
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expanded, it was clear that effective testing for the presence of neutralizing antibodies in the blood of convalescent patients would be critical for development of plasma-based therapeutic approaches. To address the need for a high-quality neutralization assay against SARS-CoV-2, a previously established fluorescence reduction neutralization assay (FRNA) against Middle East respiratory syndrome coronavirus (MERS-CoV) was modified and optimized. The SARS-CoV-2 FRNA provides a quantitative assessment of a large number of infected cells through use of a high-content imaging system. Because of this approach, and the fact that it does not involve subjective interpretation, this assay is more efficient and more accurate than other neutralization assays. In addition, the ability to set robust acceptance criteria for individual plates and specific test wells provided further rigor to this assay. Such agile adaptability avails use with multiple virus variants. By February 2021, the SARS-CoV-2 FRNA had been used to screen over 5000 samples, including acute and convalescent plasma or serum samples and therapeutic antibody treatments, for SARS-CoV-2 neutralizing titers. View Full-Text
Keywords: SARS-CoV; SARS-CoV-2; coronavirus; COVID; COVID-19; neutralization; antibodies; diagnosis SARS-CoV; SARS-CoV-2; coronavirus; COVID; COVID-19; neutralization; antibodies; diagnosis
Show Figures

Figure 1

MDPI and ACS Style

Bennett, R.S.; Postnikova, E.N.; Liang, J.; Gross, R.; Mazur, S.; Dixit, S.; Kocher, G.; Yu, S.; Georgia-Clark, S.; Gerhardt, D.; Cai, Y.; Marron, L.; Lukin, V.V.; Holbrook, M.R. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples. Viruses 2021, 13, 893. https://doi.org/10.3390/v13050893

AMA Style

Bennett RS, Postnikova EN, Liang J, Gross R, Mazur S, Dixit S, Kocher G, Yu S, Georgia-Clark S, Gerhardt D, Cai Y, Marron L, Lukin VV, Holbrook MR. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples. Viruses. 2021; 13(5):893. https://doi.org/10.3390/v13050893

Chicago/Turabian Style

Bennett, Richard S., Elena N. Postnikova, Janie Liang, Robin Gross, Steven Mazur, Saurabh Dixit, Gregory Kocher, Shuiqing Yu, Shalamar Georgia-Clark, Dawn Gerhardt, Yingyun Cai, Lindsay Marron, Vladimir V. Lukin, and Michael R. Holbrook. 2021. "Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples" Viruses 13, no. 5: 893. https://doi.org/10.3390/v13050893

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop